RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Recursion Pharmaceuticals Inc. (RXRX) shares soared 16% in Wednesday’s pre-market trade after the company’s fourth-quarter (Q4) results beat Wall Street expectations.

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

“Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value,” said Najat Khan, CEO & President of Recursion.

Retail sentiment on Stocktwits around Recursion Pharmaceuticals trended in the ‘bullish’ territory at the time of writing.

Get updates to this developing story directly on Stocktwits.<

For updates and corrections, email newsroom[at]stocktwits[dot]com.<